MedTrace Logo

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

NCT06132828 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2026-04-27

No results posted yet for this study

Summary

This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors

Conditions

Interventions

DRUG

DR30206

Subjects receive DR30206 intravenously

Sponsors & Collaborators

  • Zhejiang Doer Biologics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Caicun Zhou, MD · Shanghai Pulmonary Hospital, Shanghai, China

  • Yanshan Huang, PhD · Zhejiang Doer Biologics Co., Ltd.

  • Junfang Xu, MD · Huadong Medicine Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2027-07-30
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06132828 on ClinicalTrials.gov